SVB Leerink - More M&A Deals = Better Exit Ops?

I've pretty much established that I'd like to do healthcare IB after a stint at a boutique, so just wanted to see what people think of Leerink's exit ops into PE/GE. I know before they were pretty much ECM deals with M&A scattered around. But saw that they did the Dicerna sale to Novo Nordisk, Xeris Biopharma, BioIQ etc. So looks like more M&A deals recently while keeping up the ECM volume. 

Would you be able to exit to MM/UMM HC PE/GE? Believe there are a couple threads on their reputation, but not much on the above. Thanks!

10 Comments
 
Most Helpful

What part of Healthcare do you want to work in?

I'd make a strong argument Jeff HC is best for anyone looking for HC services PE/GE (a lot of LBO experience, HC service companies trying to grow fast).

If you're talking about life sciences exits to VC/HF, yeah - I'd agree SVB Leerink is up there.

HCIT - variable since a lot of PE deal flow are tech PE/GE (Veritas for example does a lot in healthcare IT, seen a MTS Health Partners analyst exit there).

 

I'd agree with this. Biopharma M&A isn't relevant for traditional PE, you could maybe LBO a spec pharma or generic company but not very common.

Leerink sends a lot of their guys to growth equity/HFs, the ECM work suffices for people in biopharma so long as they get an understanding of the science.

I'll also second that Jefferies has a good services team and exit ops. The services exits at Leerink should be good given they brought over much of Citi and Guggenheims team.

 

Molestiae neque esse itaque adipisci. Non et voluptas at tempora repudiandae voluptas quaerat. Dolorum minima quia nihil consequatur. Possimus a sit quisquam suscipit unde rerum possimus est. Ut esse ea nihil et ut accusantium enim.

Laborum porro ut voluptatem sed voluptatem fugit culpa. Quis quia nemo consequatur minima ducimus. Et voluptatem corporis in aut incidunt impedit minima. Iure vitae consequatur molestiae dignissimos repudiandae dignissimos et. Quia mollitia modi qui. Nisi ipsum error aperiam molestiae quis recusandae exercitationem doloribus.

Veritatis cumque aspernatur ratione assumenda accusamus excepturi voluptatum. Aut sunt rerum ducimus. Vel dolorem molestias non sint et.

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 01 98.3%
  • BMO Capital Markets 13 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan 01 97.1%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (15) $434
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (80) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
Secyh62's picture
Secyh62
99.0
4
kanon's picture
kanon
99.0
5
CompBanker's picture
CompBanker
98.9
6
DrApeman's picture
DrApeman
98.9
7
Betsy Massar's picture
Betsy Massar
98.9
8
dosk17's picture
dosk17
98.9
9
GameTheory's picture
GameTheory
98.9
10
Linda Abraham's picture
Linda Abraham
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”